Samsca (Tolvaptan) — Patient Information for UK Customers

Samsca contains the active ingredient tolvaptan. It is a medicine used to treat certain types of low sodium in the blood (hyponatraemia). This page explains what Samsca does, how it is used, what to expect, and important safety information—written for patients and carers in the United Kingdom.

Always follow the instructions provided by your healthcare professional and read the patient information leaflet supplied with your medicine.

1. Basic product information

Brand name: Samsca

Generic name: Tolvaptan

Medicine type: Vasopressin V2 receptor antagonist (a “vaptan”)

2. What is hyponatraemia?

Hyponatraemia means that the level of sodium in your blood is too low. Sodium helps control how much water is in and around cells. When sodium falls, fluid balance can become abnormal and symptoms may occur.

Hyponatraemia can happen for different reasons, for example:

• Hormonal or medication-related changes
• Certain illnesses that cause the body to retain water
• Heart, liver, or kidney conditions
• Excess fluid intake or “low solute” intake

The severity and urgency depend on how low sodium is, how quickly it dropped, and your symptoms.

3. How Samsca works (mechanism of action)

Samsca (tolvaptan) works by blocking the action of vasopressin (also called antidiuretic hormone, ADH) at the vasopressin V2 receptors in the kidney.

When vasopressin is active, the kidneys reabsorb water, which can dilute sodium in the blood. By blocking this pathway, tolvaptan helps the body remove free water (water without salts) through the urine.

This leads to an increase in blood sodium concentration in appropriate cases.

• V2 receptor antagonist → reduces water reabsorption
• “Aquaresis” → increases water excretion (diuresis of free water)
• Helps correct hyponatraemia while avoiding salt loading

4. Pharmacokinetics (how the body handles the medicine)

While individual responses vary, the following general features help explain dosing and timing:

• Absorption: Tolvaptan is absorbed after oral dosing.
• Onset: It typically starts working within hours, with urine output increasing early after a dose.
• Metabolism: Tolvaptan is metabolised in the liver (primarily by CYP enzymes, particularly CYP3A).
• Elimination: Metabolites are cleared mainly through the liver/bile and faeces, with some excretion via urine.
• Half-life: The duration of effect can last roughly a day or more, which is why dosing is commonly once daily in many regimens.

Important: Because metabolism involves liver pathways, liver function and drug interactions can significantly influence safety and effectiveness.

5. Typical use and timing

Samsca is used for the treatment of clinically significant hyponatraemia—particularly when other approaches are insufficient or when rapid correction is needed under medical supervision.

Key practical points:

• Samsca is taken as a once-daily oral dose in most regimens.
• It is usually started with careful monitoring of sodium levels, especially during initiation or dose changes.
• Do not try to “self-adjust” the dose—correction of sodium must be managed carefully.

Timing with meals: Your healthcare professional will usually advise how to take your tablets. In general, it is often prescribed with instructions regarding food effects (see below).

6. Indications (when Samsca is used)

In the UK, tolvaptan is used for the management of:

• Euvolaemic or hypervolaemic hyponatraemia (low sodium with normal or increased body fluid volume) where appropriate management is needed, and where correction is not achieved with other measures.
• Hyponatraemia in clinical settings where water retention contributes to low sodium, and an approach using aquaresis is suitable.

Not for all types of hyponatraemia: The suitability depends on the cause and severity. A clinician will determine whether Samsca is appropriate for you.

7. Dosing overview (important: follow your plan)

Dosing is individual and depends on factors such as:

• Initial sodium level
• Symptoms and urgency
• Whether the condition is euvolaemic or hypervolaemic
• Liver function
• Other medicines that may interact

General dosing principles often used:

• Start low and monitor closely, especially in the first days.
• Adjust based on response—sodium should rise to the target without overshooting.
• In many cases, treatment may be initiated in a setting where lab monitoring is possible.

Do not change your dose or stop/start the medicine without speaking to your healthcare professional.

Missed dose: If you miss a dose, follow the instructions from your clinician or pharmacist. In general, do not take an extra dose to make up for a missed tablet—talk to a healthcare professional for advice.

8. Food interactions and how to take Samsca

Food can affect tolvaptan exposure. To reduce variability, your clinician may ask you to take Samsca:

• With or without food in a consistent way (follow your personalised directions).
• After meals or on an empty stomach depending on your prescribed regimen.

Practical advice:

• Take the tablet at the same time each day.
• If your prescription instructions specify a particular relation to meals, follow them exactly.
• If you have nausea or difficulty swallowing, ask your pharmacist for tailored advice—do not alter dosing on your own.

9. Alcohol interactions

Alcohol can affect hydration status, blood pressure, and how you feel. It may also worsen dizziness or fatigue, particularly if you are already managing an illness that affects fluid balance.

General guidance:

• Limit alcohol while taking Samsca, unless your clinician advises otherwise.
• Avoid binge drinking.
• If you notice dizziness, light-headedness, or unusual weakness, avoid alcohol and seek advice.

Seek medical advice if you have liver disease, as alcohol can further impair liver function—important because tolvaptan is metabolised in the liver.

10. Interactions with medicines (including key CYP-related interactions)

Tolvaptan is metabolised in the liver (notably via CYP pathways, especially CYP3A). Therefore, medicines that inhibit or strongly induce these pathways may change tolvaptan levels.

Always tell your pharmacist or clinician about all medicines you take, including:

• Prescription medicines
• Over-the-counter products
• Herbal supplements (for example, St John’s wort)
• Vitamins and mineral products

Examples of medicines that may require extra caution (not an exhaustive list):

• CYP3A inhibitors (may increase tolvaptan exposure)
• CYP3A inducers (may reduce tolvaptan exposure)
• Other medicines affecting fluid balance or sodium levels (risk of imbalance)

Because hyponatraemia management is complex, the clinical team may monitor sodium more frequently if interacting medicines are started, stopped, or dose-adjusted.

11. Safety profile: what to watch for

Samsca can be effective for appropriate hyponatraemia, but it has important safety considerations. The main risks relate to:

• Over-correction of sodium (sodium rising too quickly)
• Dehydration or symptoms of too much water removal
• Thirst and increased urination
• Liver injury (a key risk with tolvaptan)

Common effects

• Increased urination
• Thirst
• Dry mouth
• Headache or dizziness (may occur especially early on)

Serious warnings

Please contact a healthcare professional promptly or seek urgent advice if you experience any of the following:

• Signs of dehydration: severe thirst, weakness, fainting, very dry skin/mouth, reduced urination
• Symptoms of electrolyte imbalance or rapid changes: confusion, severe headache, worsening drowsiness, seizures (depending on clinical context)
• Liver-related symptoms such as yellowing of the skin/eyes (jaundice), dark urine, unusual fatigue, nausea with right upper abdominal discomfort
• Severe allergic reaction: swelling of face/lips, trouble breathing, widespread rash

Liver monitoring: Tolvaptan has a known risk of liver injury, and patients are typically monitored with blood tests. Your clinician will explain the schedule and what to do if abnormalities occur.

12. Practical use tips for UK patients

These tips can help you use Samsca safely and make monitoring easier:

• Attend all blood test appointments: sodium and liver function may need regular checks, especially early in treatment or after changes.
• Keep track of urine output: increased urination is expected, but extreme changes can signal imbalance—report concerns.
• Manage thirst appropriately: follow the advice you receive regarding fluid intake. Do not abruptly overdrink “to counteract” the medicine unless your clinician tells you to.
• Be cautious when getting up: dizziness can happen; stand up slowly.
• Maintain consistency with meals: take the tablet as directed regarding food.
• Avoid dehydration risks: hot weather, vomiting/diarrhoea, or strenuous activity can increase risk—seek guidance if you are unwell.

Important note on correcting sodium: Treatment aims to raise sodium to a safe level, not necessarily to “normal” quickly. Rapid changes can be harmful; monitoring is designed to reduce this risk.

13. Alternative options for hyponatraemia

Alternative treatments depend strongly on the cause of hyponatraemia. Your healthcare team may consider:

• Fluid restriction (often first-line for some chronic cases)
• Salt and/or loop diuretics (depending on volume status and cause)
• Hypertonic saline in severe symptomatic cases (in hospital settings)
• Urea in some scenarios to increase solute intake and help correct sodium
• Other “vaptan” medicines in certain contexts (your clinician will decide if appropriate)

Which option is best depends on your symptoms, speed of onset, underlying conditions, and current medications.

14. Market and legal context in the UK

In the United Kingdom, medicines containing tolvaptan are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). Medicines must comply with UK legislation regarding quality, safety, and supply chain management.

Patients should be aware of the following practical points:

• Authorisation and prescribing rules: The use of Samsca is governed by UK clinical guidance, product information, and safety monitoring requirements.
• Patient information: The Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL) provide authoritative details on dosing, contraindications, and monitoring.
• Safety monitoring: Because of liver-related risks and the need to correct sodium carefully, UK pathways typically include monitoring and patient selection.

Recent guidance: Clinical practice continues to emphasise careful sodium correction and monitoring, alongside ongoing liver safety awareness for tolvaptan-containing therapies. Always check for updated local advice through your healthcare provider.

15. Delivery and availability (UK)

Availability can vary by supplier and stock levels. When ordering through a UK online pharmacy, deliveries are generally subject to:

• Product availability at dispatch
• Strength and pack size requested
• Local courier services and delivery area coverage

Delivery expectations:

• Orders are typically processed and dispatched on working days.
• Estimated delivery times are usually provided at checkout.
• If a product is temporarily out of stock, the pharmacy should inform you and suggest alternatives or next steps.

Storage at home:

• Store tablets in their original packaging.
• Protect from excessive heat, moisture, and light.
• Keep out of sight and reach of children.

16. Frequently Asked Questions (FAQ)

How quickly does Samsca start working?

Many people notice increased urination within the first hours after taking a dose. Blood sodium changes are managed through monitoring and depend on your underlying condition and baseline sodium level.

Why do I need blood tests?

Sodium levels must be corrected safely to avoid over-correction. Tolvaptan also carries a liver risk, so liver function tests are often required during treatment.

Will Samsca make me urinate more?

Yes. Because tolvaptan promotes excretion of free water, increased urine output and thirst are common. Follow your clinician’s guidance on fluid intake.

Can I drink water normally?

Do not dramatically increase or restrict fluids without medical advice. Your clinician will provide a plan based on your sodium level, symptoms, and treatment goals.

Can I take Samsca with food?

You should follow your specific prescription instructions regarding meals. Food can influence tolvaptan exposure, so it’s best to take it consistently as directed.

Is it safe to drink alcohol?

Alcohol is best limited while taking Samsca because it can affect hydration and may worsen dizziness. If you have liver problems or drink regularly, discuss with a healthcare professional.

What medicines should I avoid?

Some medicines may interact with tolvaptan (especially those affecting liver enzymes like CYP3A) or may influence fluid/electrolyte balance. Tell your pharmacist about all medicines and supplements you use.

What should I do if I feel dizzy?

Dizziness can happen, especially early in therapy. Avoid driving or operating machinery if you feel unsteady. Sit or lie down and seek advice promptly if symptoms are severe or persistent.

What are the signs of liver problems?

Seek urgent advice if you notice yellow skin/eyes (jaundice), dark urine, severe fatigue, or persistent upper right abdominal discomfort.

Can I stop taking Samsca when I feel better?

Do not stop or change the dose without medical guidance. Stopping suddenly may lead to recurrence of hyponatraemia depending on the cause.

Is Samsca suitable for everyone with low sodium?

No. Suitability depends on the type and cause of hyponatraemia, your symptoms, and overall health status (including liver function and interacting medicines).

17. Summary

Samsca (tolvaptan) is a vasopressin V2 receptor antagonist used to treat selected forms of hyponatraemia by increasing excretion of free water (aquaresis). It can raise blood sodium, but it requires careful monitoring to prevent over-correction and because liver-related safety risks exist. If you are prescribed Samsca, take it exactly as directed, follow food timing instructions, keep appointments for blood tests, and contact your healthcare professional promptly if you develop symptoms such as excessive dehydration, confusion, or signs of liver injury.